GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Desmopressin - DDAVP injection

Local official-label summaryBase record retrieved 2026-09-10See the evidence for this drug2 sources available - open source summaries, references and comparisons

DDAVP injection / desmopressin acetate injection

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

A labeled renal contraindication is not a reduced-dose suggestion

Both selected sources contraindicate CrCl below 50. The official injection source specifies Cockcroft-Gault and preserves sodium/fluid precautions.

Before applying: Confirm the injectable product, indication, contraindicated medicines and sodium/volume status. This record does not adjudicate specialist off-label uremic bleeding.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Desmopressin - DDAVP injection

Product / population
DDAVP 4 mcg/mL injection, IV or SC according to its indication; selected labeled DI/hemophilia A/type I vWD context, not a uremic-bleeding protocol.
Renal measure
Cockcroft-Gault CrCl in mL/min; 8.6
Before using this finding

The label restriction is not bypassed by lowering the dose; off-label nephrology use is not adjudicated here.

Selected named sections only; not a complete monograph or independent clinical approval.

Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.

Renal dosing, restrictions and evidence limits

DDAVP injection is contraindicated below Cockcroft-Gault CrCl 50 mL/min. Ensure normal sodium before initiation or resumption. For treatment monitoring, reassess sodium within 1 week, at about 1 month and periodically; increase frequency for older patients and other high-risk groups. Minimize fluid intake from 1 hour before until 8 hours after administration. Loop diuretics, systemic/inhaled glucocorticoids, hyponatremia/history, SIADH, polydipsia, relevant acute illness, heart failure and uncontrolled hypertension carry contraindications. Monitor blood pressure during administration. The PK study is not a renal-dose ladder or a dialysis regimen.

Source revision: 7/2022 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=651f6fee-a2c7-431b-8d5d-58b156c72244

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Desmopressin - DDAVP injection

Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

GlobalRPh RX List - DDAVP injection

Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Desmopressin - DDAVP injection

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

The label restriction is not bypassed by lowering the dose; off-label nephrology use is not adjudicated here.

Dialysis evidence: No dialysis regimen established in selected content

DDAVP 4 mcg/mL injection, IV or SC according to its indication; selected labeled DI/hemophilia A/type I vWD context, not a uremic-bleeding protocol.

Renal method: Cockcroft-Gault CrCl in mL/min; 8.6
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - DDAVP injection

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Check product, renal function, serum sodium, fluid status and contraindicated concomitant medicines before use.

Dialysis evidence: No dialysis regimen established in selected content

DDAVP 4 mcg/mL injection, IV or SC according to its indication; selected labeled DI/hemophilia A/type I vWD context, not a uremic-bleeding protocol.

Renal method: CrCl in mL/min; see exact official label for Cockcroft-Gault definition
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

A labeled renal contraindication is not a reduced-dose suggestion

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

formulation and contraindication scope

A labeled renal contraindication is not a reduced-dose suggestion

Both selected sources contraindicate CrCl below 50. The official injection source specifies Cockcroft-Gault and preserves sodium/fluid precautions.

How to use this: Confirm the injectable product, indication, contraindicated medicines and sodium/volume status. This record does not adjudicate specialist off-label uremic bleeding.

GlobalRPh RX List - DDAVP injectionDesmopressin - DDAVP injectionDesmopressin - DDAVP oral tabletsDesmopressin - NOCDURNA sublingual tabletsDesmopressin - NOCTIVA nasal spray

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeDesmopressin - DDAVP injectionGlobalRPh RX List - DDAVP injection
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/ddavp-injection-drug/

Exact product and population

DDAVP 4 mcg/mL injection, IV or SC according to its indication; selected labeled DI/hemophilia A/type I vWD context, not a uremic-bleeding protocol.

RDM60-SCOPE-desmopressin-ddavp-injection · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Desmopressin - DDAVP injection

Open original reference

Open / share this exact local source

DailyMed / Ferring Pharmaceuticals Inc. · DDAVP 4 mcg/mL injection, IV or SC according to its indication; selected labeled DI/hemophilia A/type I vWD context, not a uremic-bleeding protocol.

Renal method: Cockcroft-Gault CrCl in mL/min; 8.6
Source date: 7/2022
Retrieved: 2026-09-10

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

The label restriction is not bypassed by lowering the dose; off-label nephrology use is not adjudicated here.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

DDAVP injection is contraindicated below Cockcroft-Gault CrCl 50 mL/min. Ensure normal sodium before initiation or resumption. For treatment monitoring, reassess sodium within 1 week, at about 1 month and periodically; increase frequency for older patients and other high-risk groups. Minimize fluid intake from 1 hour before until 8 hours after administration. Loop diuretics, systemic/inhaled glucocorticoids, hyponatremia/history, SIADH, polydipsia, relevant acute illness, heart failure and uncontrolled hypertension carry contraindications. Monitor blood pressure during administration. The PK study is not a renal-dose ladder or a dialysis regimen.

RDM60-official-desmopressin-ddavp-injection-9a4c7421a9-C1 · Source locator: Boxed warning; 2.1; 4; 5.1-5.2; 8.6

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=651f6fee-a2c7-431b-8d5d-58b156c72244
Retrieved
2026-09-10
Exact label title
Desmopressin - DDAVP injection
DailyMed Set ID
651f6fee-a2c7-431b-8d5d-58b156c72244
Labeler
Ferring Pharmaceuticals Inc.
DailyMed page updated
2022-09-28
Label revision
7/2022
Renal-function method
Cockcroft-Gault CrCl in mL/min; 8.6
Source date/version
7/2022
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
873640134c9cd66137333d0288af044ba2b70757c321acce77060ce52b42cae0
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - DDAVP injection

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · DDAVP 4 mcg/mL injection, IV or SC according to its indication; selected labeled DI/hemophilia A/type I vWD context, not a uremic-bleeding protocol.

Renal method: CrCl in mL/min; see exact official label for Cockcroft-Gault definition
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

Check product, renal function, serum sodium, fluid status and contraindicated concomitant medicines before use.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The mirror contraindicates DDAVP injection at CrCl below 50 mL/min. Hyponatremia/history, SIADH, polydipsia, loop diuretics, systemic or inhaled glucocorticoids, fluid/electrolyte-disturbing illness, heart failure and uncontrolled hypertension have separate contraindication statements. Impaired-renal PK findings do not supply a reduced-dose exception. These restrictions concern the named injection and labeled uses; other desmopressin products and specialist off-label uses require their own review.

RDM60-rxlist-desmopressin-ddavp-injection-46fb0aff4f-C1 · Source locator: Contraindications; geriatric use; renal PK

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. See the separately attributed official source; concordance is limited to selected sections.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/ddavp-injection-drug/
Retrieved
2026-09-10
Renal-function method
CrCl in mL/min; see exact official label for Cockcroft-Gault definition
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
044aef28752f45c12a4abad2b29be6c1df2ae3a4cdff478dcf948e70f7ce8b45

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/ddavp-injection-drug/
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
2dabf24fdd01042b5eabf681cd7c9d705878bf33ea57b4547ff95d18b3d84927
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report